Company news

MannKind Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference

March 6, 2023

MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results

February 22, 2023

MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference

February 21, 2023

MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023

February 15, 2023

Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference

February 9, 2023

MannKind Corporation to Participate in the Lytham Partners Investor Select Conference

January 23, 2023

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

January 22, 2023

MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference

January 4, 2023

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

November 9, 2022

MannKind Corporation Reports 2022 Third Quarter Financial Results

November 7, 2022

MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022

October 31, 2022

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference

September 20, 2022

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine

September 5, 2022

MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 31, 2022

MannKind Corporation Reports 2022 Second Quarter Financial Results

August 8, 2022

MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022

August 1, 2022

MannKind Corporation to Participate in the BTIG Biotechnology Conference

July 31, 2022

Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7

June 2, 2022

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

May 23, 2022

MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell

May 18, 2022

MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma

May 16, 2022

MannKind Corporation Participating at Upcoming Conferences

May 8, 2022

MannKind Corporation Reports 2022 First Quarter Financial Results

May 4, 2022

MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022

April 27, 2022

MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30

April 26, 2022

MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference

March 27, 2022

MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit

March 21, 2022

MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference

March 7, 2022

Update on Tyvaso DPI™ New Drug Application

February 23, 2022

MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results

February 23, 2022

MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022

February 20, 2022

MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference

February 9, 2022

MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

January 4, 2022

MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference

January 4, 2022

MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference

December 5, 2021

MannKind Corporation Reports 2021 Third Quarter Financial Results

November 8, 2021

Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

November 8, 2021

MannKind Presents Data at 21st Annual Diabetes Technology Meeting

November 4, 2021

MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021

November 1, 2021

Progress Update on Tyvaso DPI™ New Drug Application

October 17, 2021

MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population

October 3, 2021

Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

September 28, 2021

MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference

September 27, 2021

Mannkind Corporation Participating at Upcoming Conferences

September 14, 2021

MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021

August 23, 2021

MannKind Corporation Reports 2021 Second Quarter Financial Results

August 10, 2021

MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform

August 3, 2021

MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021

August 3, 2021

MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021

August 2, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.